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Mvwf, a Dominant Modifier of Murine
von Willebrand Factor, Results from Altered
Lineage-Specific Expression of a Glycosyltransferase
Inheritance of type 1 VWD is generally autosomal domi-
nant, though with reduced penetrance and variable ex-
pressivity. VWF gene mutations have been identified
in a subset of type 1 VWD individuals. However, the
molecular defects responsible for most cases remain
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The highly variable expressivity and incomplete pene-The University of Michigan
Ann Arbor, Michigan 48109-0650 trance of VWD, as well as the wide range of plasma VWF
levels among normal individuals, has made it difficult
to study potential VWF modifier genes in humans. The
mouse has proven to be a powerful model organism forSummary
the dissection of genetic factors contributing to complex
disorders (Todd et al., 1991) and the identification ofWe have identified altered lineage-specific expres-
modifier genes for variable phenotypes such as cancersion of an N-acetylgalactosaminyltransferase gene,
predisposition (MacPhee et al., 1995) and infectious dis-Galgt2, as the gain-of-function mechanism responsi-
ease susceptibility (Vidal et al., 1993; Bellamy et al.,ble for the action of the Mvwf locus, a major modifier
1998). We previously defined a major modifying locusof plasma von Willebrand factor (VWF) level in RIIIS/J
for plasma VWF levels in RIIIS/J mice that we termedmice. A switch of Galgt2 gene expression from intesti-
Mvwf. RIIIS/J plasma VWF levels are reduced by up tonal epithelial cell-specific to a pattern restricted to the
20-fold, when compared to other inbred strains (Sweeneyvascular endothelial cell bed leads to aberrant post-
et al., 1990; Nichols et al., 1994). RIIIS/J mice also exhibittranslational modification and rapid clearance of VWF
other characteristics similar to human type 1 VWD, in-from plasma. Transgenic expression of Galgt2 directed
cluding prolonged bleeding time and normal VWFto vascular endothelial cells reproduces the low VWF
multimer structure. Low VWF levels are inherited as anphenotype, confirming this switch in lineage-specific
essentially pure autosomal dominant trait (Sweeney etgene expression as the likely molecular mechanism
al., 1990), suggesting a gain-of-function mutation mech-for Mvwf. These findings identify alterations in glyco-
anism (Mohlke et al., 1996). In an intercross betweensyltransferase function as a potential general mecha-
RIIIS/J and CASA/Rk, an inbred strain of Mus musculusnism for the genetic modification of plasma protein
castaneus, we mapped the Mvwf locus to a z0.3 centi-levels.
morgan (cM) interval on distal mouse chromosome 11
(Mohlke et al., 1998), distinct from the murine Vwf geneIntroduction
on chromosome 6 (Mohlke et al., 1996; Nichols et al.,
1994).von Willebrand factor (VWF) is a multimeric plasma gly-
We now report the identification of Mvwf as a gain-coprotein that plays an essential role in hemostasis.
of-function regulatory mutation in the gene encoding anIn plasma, VWF stabilizes coagulation factor VIII and
N-acetylgalactosaminyltransferase, GALGT2. The RIIIS/Jmediates the adhesion and aggregation of platelets to
Mvwf allele switches Galgt2 gene expression from pre-the subendothelium at sites of vascular injury, especially
dominantly gastrointestinal epithelial cell-specific to aunder conditions of high shear (Savage et al., 1996).
pattern largely restricted to the vascular endothelial cell,VWF is synthesized exclusively in megakaryocytes and
the latter coincident with the site of plasma VWF synthe-endothelial cells and is often used as a specific marker
sis. The resulting aberrant posttranslational modifica-for the endothelial cell lineage. Endothelial cell±derived
tion of VWF by GALGT2 leads to dramatically increasedVWF can be secreted by a constitutive pathway or can
clearance from plasma, accounting for the low VWFinduce the formation of Weibel-Palade bodies for regu-
phenotype.lated secretion (Wagner et al., 1991). Extensive post-
translational modification of VWF includes glycosyla-
tion, sulfation, multimerization, and propeptide cleavage Results
(Nichols and Ginsburg, 1997).
Qualitative or quantitative abnormalities of VWF func- To identify the gene responsible for low plasma VWF
tion result in von Willebrand disease (VWD), the most level in RIIIS/J mice, candidate transcripts previously
common inherited bleeding disorder of humans, with mapped to the 0.3 cM, z300 kb Mvwf region on mouse
prevalence estimated at up to 1% of the population chromosome 11 (Mohlke et al., 1998) were surveyed for
(Rodeghiero et al., 1987). Seventy percent of VWD is mutations. Of the seventeen putative expressed se-
classified as type 1, characterized by quantitative reduc- quences in this region, complete coding sequence was
tion of plasma VWF to 20%±50% of the normal level. available for an ATP synthase (Atp6n1), gastric inhibitory
peptide (Gip), and a known but previously unmapped
gene encoding an N-acetylgalactosaminyltransferase‖ To whom correspondence should be addressed (e-mail: ginsburg@
umich.edu). that we termed Galgt2. The enzyme activity associated
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predicted size was observed in the small intestine sam-
ple from the CASA/Rk mouse but not in any tissues from
the RIIIS/J mouse. Levels of Galgt2 mRNA detected
in small intestine from two additional wild-type strains
(C57BL/6J and 129/Sv) were similar to CASA/Rk, and the
level from an (RIIIS/J 3 CASA/Rk) F1 mouse appeared to
be decreased by approximately 50% (data not shown).
These results indicate that the gastrointestinal-specific
expression of Galgt2 observed in most wild-type mouse
strains has been lost in RIIIS/J.
Normal Plasma VWF Levels
Figure 1. Relative Allelic Expression of Mvwf Candidate Genes in Galgt2-Deficient Mice
Sequencing chromatograms of RNA PCR product amplified from The observation of apparently reduced Galgt2 expres-
small intestine RNA (Galgt2) or liver RNA (Atp6n1). The relevant sion in RIIIS/J mice suggested that maintenance of nor-polymorphic nucleotide (underlined) is coincidentally a C in the
mal plasma VWF levels might require a threshold levelCASA/Rk allele and a T in the RIIIS/J allele for both genes. Equal
of GALGT2, above that present in heterozygous F1 mice.quantities of parental RNA PCR products were combined prior to
sequencing to form the 1:1 mix controls. One of two (RIIIS/J 3 To test this hypothesis, we assayed VWF from plasma
CASA/Rk)F1 samples analyzed for each gene is shown. The control of mice lacking Galgt2. Galgt2-deficient mice generated
1:1 mix samples for both genes and the F1 PCR product for Atp6n1 by embryonic stem cell targeting are viable and fertile
show equal expression from both alleles (N). In contrast, only ex- (P. L. Smith and J. B. Lowe, unpublished data). Plasmapression from the CASA/Rk allele is seen for Galgt2 amplified from
VWF level was measured in three female and three malethe F1 mRNA.
11-week-old Galgt2-deficient mice (produced from an
eight-generation backcross to C57BL/6J). The mean
with the Galgt2 gene generates the T lymphocyte± VWF level of Galgt2-deficient mice (0.10 6 0.05 units/
specific CT oligosaccharide differentiation antigen, and ml) was not significantly different from the mean for 13
the human homolog of Galgt2 is thought to generate control C57BL/6J mice (0.13 6 0.04 units/ml, P . 0.24).
the structure recognized as the human blood group Sda These results indicate that Galgt2 gene expression is
oligosaccharide (Smith and Lowe, 1994). As we pre- not required for the maintenance of normal plasma VWF
viously reported, sequence analysis of RNA PCR prod- levels and that Mvwf is not a simple loss-of-function
ucts spanning the coding regions for these three genes mutation in Galgt2.
failed to identify any clearly significant amino acid differ-
ences (Mohlke et al., 1998).
The Dlb1 Polymorphism Requires
Expression of Galgt2Altered Galgt2 Expression in Mice
with Low Plasma VWF Examination of available genetic maps for mouse chro-
mosome 11 (Watkins-Chow et al., 1996) identified a his-To screen for transcriptional regulatory mutations in the
Atp6n1, Gip and Galgt2 loci, we used an RNA PCR strat- tologic polymorphism termed Dlb1, which was function-
ally mapped by Uiterdijk et al. in 1986 to a region (3.1 6egy (Nichols et al., 1991) to detect potential allelic differ-
ences in expression of the cognate mRNAs. The inciden- 1.4 cM proximal to Re; Uiterdijk et al., 1986) potentially
overlapping the Mvwf candidate interval. Dlb1 was firsttal identification of neutral DNA variation during the
initial sequencing facilitated this approach. Analysis of detected in mouse small intestine sections with the plant
lectin termed Dolichos biflorus agglutinin (DBA) by Pon-tissue from heterozygote mice allowed a direct compari-
son of mRNA expression from the mutant and wild-type der and colleagues in 1983 (Ponder and Wilkinson, 1983)
and was subsequently used as a lineage-specific markeralleles. In order to determine the relative expression
levels of the RIIIS/J and CASA/Rk alleles at these three for intestinal epithelial cell migration (Ponder et al.,
1985b; Schmidt et al., 1985). The DBA lectin recognizescandidate loci, RNA PCR products spanning polymor-
phic nucleotides were amplified from total RNA pre- terminal nonreducing N-acetylgalactosamine (GalNAc)
residues. The Dlb1 polymorphism is characterized bypared from liver (Atp6n1) or small intestine (Gip and
Galgt2) of RIIIS/J, CASA/Rk, and (RIIIS/J 3 CASA/Rk)F1 DBA binding primarily restricted to the intestinal epithe-
lium of C57BL/6 and most other mouse strains, in con-mice (abbreviated F1). Atp6n1 and Gip PCR products
from F1 RNA showed equivalent expression from both trast to the pattern of DBA binding to the vascular endo-
thelium and absence from the epithelium observed inalleles (Figure 1 and data not shown). In contrast, Galgt2
mRNA amplification from F1 samples only detected a the RIII strain (an ancestral strain of RIIIS/J). Though the
nature of the locus that determined expression of DBA-signal from the CASA/Rk allele (Figure 1). These results
suggested that the CASA/Rk allele of Galgt2 is preferen- positive tissues was not known, this lectin's specificity
for GalNAc and GalNAc-substituted glycans suggestedtially expressed in F1 mice.
To further characterize the apparently altered Galgt2 that the Dlb1 polymorphism was determined by tissue-
specific expression of a GalNAc transferase (Ponder etmRNA expression pattern in RIIIS/J mice, a Galgt2
RNase protection assay was performed on small in- al., 1985a).
To examine the potential relationship between Dlb1testine, kidney, liver, lung, spleen, and brain of adult
RIIIS/J and CASA/Rk mice. A protected fragment of the and Galgt2, we used immunofluorescence to examine
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Figure 2. Altered Cell-Type Expression of
Galgt2
Frozen sections of small intestine from
C57BL/6J, Galgt2-deficient (Galgt22/2),
CASA/Rk, RIIIS/J, and (RIIIS/J 3 CASA/Rk)F1
mice were visualized with DBA lectin (green)
and anti±von Willebrand factor antibody (red).
The DBA lectin signal is restricted to intestinal
epithelial cells in C57BL/6J and CASA/Rk and
to endothelial cells in RIIIS/J. Both types of
cells are labeled in (RIIIS/J 3 CASA/Rk)F1,
whereas no signal is seen in the Galgt22/2
section. The VWF antibody detects endothe-
lial cells lining the vessels of the lamina pro-
pria located in the center of the intestinal villi
and shows a similar pattern in each section.
The bottom row shows a composite of the
VWF and DBA lectin staining.
the DBA-binding pattern in the small intestine of C57BL/ by the DBA lectin is the result of a switch in cell-type-
specific Galgt2 gene expression from gastrointestinal6J and Galgt2-deficient mice. Sections of small intes-
tines were simultaneously analyzed with the DBA lectin epithelial to vascular endothelial cells, rather than varia-
tion in the availability of a specific glycoprotein substrateand a polyclonal rabbit anti-human VWF antibody as a
marker for endothelial cells (Figure 2). In the C57BL/6J or altered localization of GalNAc-decorated proteins
synthesized at other sites. The much greater overall levelsample, the DBA lectin bound to the villus epithelial
cells, confirming the earlier report (Ponder et al., 1985a), of Galgt2 expression in the colon of C57BL/6J compared
to that in RIIIS/J, as evident by in situ hybridizationwhereas no lectin-binding was observed in Galgt2-defi-
cient mice. These results demonstrate that the sugar (Figure 3), also explains the failure to detect a signal
from the RIIIS/J allele of the F1 mouse in the competitivestructure detected by the DBA lectin in small intestine
tissue sections requires the presence of the Galgt2 gene RNA PCR experiment shown in Figure 1.
To explain how the altered Galgt2 cell-type expressionproduct.
pattern results in reduced plasma VWF levels, we pro-
posed the model shown in Figure 4. In most mouseAltered Cell-type Expression of Galgt2
strains, Galgt2 is expressed primarily in the intestinalin RIIIS/J Mice
epithelium, but not in the vascular endothelium, the pri-To determine if altered Galgt2 expression in the RIIIS/J
mary site of VWF biosynthesis. In such strains of mice,strain is responsible for the Dlb1 polymorphism, we per-
posttranslational modification of VWF would not includeformed immunofluorescence on sections from RIIIS/J,
glycan modification catalyzed by GALGT2. However inCASA/Rk, and F1 progeny of a cross between the two
RIIIS/J mice, a switch of Galgt2 gene expression to thestrains. In the RIIIS/J sample, the DBA lectin signal was
endothelial cell compartment leads to GALGT2-medi-absent from the epithelial cells but was present in the
ated transfer of GalNAc onto the glycans that decoratecentral vessels of the villi and colocalized with VWF
endothelial cell-synthesized proteins, including VWF.staining. In the CASA/Rk sample, the DBA lectin bound
GalNAc-decorated VWF in this strain is consequentlyto the villus epithelial cells, as had been observed in
secreted in an inefficient manner, or, alternatively, isC57BL/6J mice, but the villus microvasculature did not
more rapidly cleared from plasma, resulting in the ob-bind the lectin. The F1 sample showed DBA lectin-bind-
served reduction in VWF level.ing to both epithelial and endothelial cells, consistent
with codominance of the two Galgt2 expression patterns
(Figure 2). GALGT2-Mediated Transfer of GalNAc onto VWF
To determine if VWF can display the proper precursorAdditional tissues were analyzed for DBA-binding in
all of the above strains. In RIIIS/J and F1 mice, the DBA sugar structure substrate for modification by GALGT2,
recombinant VWF was synthesized in the presence orsignal was present in major blood vessels of the spleen
and kidney and was coincident with the location of VWF, absence of GALGT2 and subsequently assayed for the
GalNAc modification. Control CHO cells and CHO cellsas observed in the intestinal microvasculature. No DBA
signal was detected in these tissues in the other mouse stably expressing Galgt2 were transiently transfected
with an expression vector containing the full-length hu-strains, aside from staining in a subset of kidney tubules
in C57BL/6J mice (data not shown). man VWF cDNA. Conditioned media prepared from both
cell types contained similar levels of VWF antigen. MediaAnalysis of Galgt2 mRNA expression by in situ hybrid-
ization detected a strong signal in the colon epithelium were also analyzed by a modified sandwich ELISA for the
presence of DBA-detectable GalNAc on VWF. A strongof C57BL/6J, with no specific signal evident in the
spleen. In contrast, in the RIIIS/J mouse, Galgt2 expres- signal was observed for VWF synthesized in Galgt2-
expressing cells (.12 3 background). In contrast, nosion was clearly evident in the splenic vascular endothe-
lium but was undetectable in the colon (Figure 3). These DBA-specific signal was detected for VWF synthesized
in control Galgt2-negative cells. These results indicatedata demonstrate that the Dlb1 polymorphism detected
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Figure 3. Galgt2 RNA In Situ Hybridization
RNA in situ hybridization was performed with a Galgt2 probe using colon (A and C) and spleen (B and D) sections from C57BL/6J (A and B)
and RIIIS/J (C and D) mice. A strong signal is seen in the colonic epithelium of C57BL/6J and is absent from the corresponding RIIIS/J section.
In contrast, the specific staining seen in the endothelial cells of large vessels in the spleen of RIIIS/J is absent from C57BL/6J.
that GALGT2 can modify the human VWF protein to levels, we measured the clearance rate of exogenously
administered, epitope-tagged, recombinant human VWFcontain the structure recognized by the DBA lectin and
that this reactivity is not detectable in the absence of with or without modification by GALGT2. Concentrated
conditioned media containing these recombinant formsGalgt2.
To determine if a significant fraction of RIIIS/J mouse of VWF were injected into the tail veins of C57BL/6J
mice. Blood samples were subsequently collected atplasma VWF contains the GALGT2-dependent structure
recognized by the DBA lectin, plasma samples were times up to 45 min postinjection, and the relative amount
of epitope-tagged VWF was determined. VWF modifiedtested in the same DBA-VWF ELISA. No DBA-detectable
GalNAc signal was observed in RIIIS/J, CASA/Rk, F1, by GALGT2 was cleared rapidly from plasma, relative to
unmodified VWF (Figure 5). The half-life (t1¤2) of modifiedC57BL/6J, or Galgt2-deficient mice, suggesting that few
or no terminal GalNAc residues are present on circulat- VWF was z25 min, while the t1¤2 of unmodified VWF was
z300 min. The latter value is comparable to the z4 hring murine plasma VWF. These results are consistent
with the hypothesis that GALGT2-modified VWF is either t1¤2 of recombinant human VWF in the rat (Stoddart et
al., 1996) or dog (Schwarz et al., 1997) though shortervery rapidly cleared from plasma or inefficiently synthe-
sized or secreted from the endothelial cell compartment than the 8±16 hr t1¤2 observed for plasma-derived VWF
in humans. These results suggest that the reduced level(Figure 4).
of VWF observed in RIIIS/J plasma is due to accelerated
clearance of GALGT2-modified VWF. The previous re-VWF Modified by GALGT2 Is Rapidly Cleared
To distinguish among these potential mechanisms for port that RIIIS/J mice exhibit normal levels of platelet
VWF (Sweeney et al., 1990) is also consistent with thisthe GALGT2-dependent modification of plasma VWF
Figure 4. Model for Mechanism of Mvwf
Action
In most mouse strains, Galgt2 is expressed
primarily in intestinal epithelial cells and Vwf
is expressed in vascular endothelial cells.
VWF secreted from endothelial cells circu-
lates in the plasma at normal steady-state
levels. However in RIIIS/J mice, Galgt2 ex-
pression is switched from epithelial to endo-
thelial cells, leading to the transfer of GalNAc
(black pentagons) onto oligosaccharides pres-
ent on VWF. The novel sugar structure on the
secreted VWF results in decreased steady-
state plasma levels, either through interfer-
ence with the secretory pathway or more
rapid clearance of VWF from plasma.
A Modifier Gene for Plasma von Willebrand Factor
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Figure 5. Altered Clearance of VWF Modified by GALGT2
Human recombinant c-myc-epitope-tagged VWF synthesized in the
presence (squares on dotted lines) or absence (circles on solid lines)
of GALGT2 was injected into C57BL/6J mice. Amounts of c-myc-
epitope-tagged VWF in plasma samples collected at 1, 10, 25, and
45 min postinjection were determined and are shown as percent of
amount detected at 1 min. In the experiments indicated by penta-
gons on dashed lines, excess asialofetuin as competitor was in- Figure 6. Transgenic Expression of Galgt2 in Endothelial Cells Re-
jected immediately prior to injection of GALGT2-modified VWF. Each sults in Decreased Plasma VWF
line represents the results obtained from a single mouse. (A) Structure of the 15 kb transgene construct, showing the murine
Tie2 promoter, the murine Galgt2 cDNA with a 23 bp deletion engi-
neered as a marker into the 39UTR, SV40 intron and poly A signalshypothesis, since VWF synthesized in the megakaryo-
(pA), and the murine Tie2 enhancer fragment.
cyte and sequestered within the platelet a granule (B) Plasma VWF levels of transgenic progeny generated from two
should be protected from accelerated clearance. transgenic founders mated to CASA/Rk. Six transgenic progeny
The high affinity of the asialoglycoprotein receptor for (black bars) have significantly lower plasma VWF levels than nine
non-transgenic littermates (gray bars). The average VWF level instructures containing subterminal GalNAc (up to 60-fold
CASA/Rk mice is arbitrarily defined as 1.0 unit/ml.greater than for galactose residues exposed following
removal of terminal sialic acids; Kolatkar et al., 1998)
suggests that GALGT2-modified VWF may be cleared plasma VWF phenotype characteristic of the RIIIS/J
Mvwf allele.via this receptor. To test this hypothesis, the disappear-
ance of modified VWF was measured following the bolus
infusion of excess asialofetuin, a competitive ligand for Discussion
the asialoglycoprotein receptor. Under these conditions,
clearance of GALGT2-modified VWF was temporarily Taken together, the data reported here identify a novel
mechanism for the inherited deficiency of a specificextended to a rate similar to that of unmodified VWF
(Figure 5). These results suggest that the accelerated plasma protein. Reduction of plasma VWF in the RIIIS/J
mouse was shown to be due to a gain-of-function regu-clearance of GALGT2-modified VWF is mediated via the
asialoglycoprotein receptor. latory mutation in a previously known glycosyltransfer-
ase enzyme, GALGT2, resulting in its switch from a pre-
dominantly gastrointestinal epithelial cell to a vascularEndothelial Cell-Specific Galgt2 Expression
Is Sufficient to Reduce Plasma VWF endothelial cell±specific pattern of expression. This al-
tered expression results in aberrant posttranslationalTo confirm the hypothesis that endothelial cell expres-
sion of Galgt2 is sufficient to lower plasma VWF level, modification leading to rapid clearance of VWF from
plasma, as confirmed by the low VWF phenotype ob-we generated mice carrying a Galgt2 transgene under
the control of the vascular endothelial cell±specific served in mice carrying an endothelial cell±specific
Galgt2 transgene.mouse Tie2 promoter and enhancer (Schlaeger et al.,
1997) (Figure 6A). The average plasma VWF level of nine
independent founder transgenic mice (0.09 6 0.07 U/ml) Glycosyltransferase Polymorphisms as Genetic
Modifiers of Human VWDwas significantly lower than the average level of 22 non-
transgenic littermates (0.19 6 0.11 U/ml, P , 0.02). Two The most common form of VWD in humans (type 1)
results from quantitative decreases in plasma VWF totransgenic founders with plasma VWF levels of 0.06 and
0.04 U/ml were mated to CASA/Rk mice to generate 20%±50% of the normal level. Thus, a reduction of
plasma VWF in the range produced by Mvwf (2- to 20-progeny on a genetic background of high VWF levels.
Transgenic progeny showed significantly lower plasma fold) would be expected to produce clinically significant
bleeding. Though at least some cases of human type 1VWF levels (0.11 6 0.05 U/ml) than their nontransgenic
littermates (0.40 6 0.20 U/ml, P , 0.005) (Figure 6B). VWD are associated with haploinsufficiency at the VWF
locus, the existence of locus heterogeneity has beenThese levels compare to the values of 0.06 U/ml for
RIIIS/J mice, 0.14 U/ml for (RIIIS/J 3 CASA/Rk)F1 mice, suggested (Ginsburg and Bowie, 1992; Mohlke and
Ginsburg, 1997) including the possibility of mutationsand 1.0 U/ml for CASA/Rk mice. These results demon-
strate that expression of Galgt2 directed to the endothe- resulting in altered posttranslational processing (Stod-
dart et al., 1996). However, a clear example of humanlial cell compartment is sufficient to reproduce the low
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VWD unlinked to the VWF locus has not yet been re- to produce aberrant hepatic cellular morphology (Ihara
et al., 1998). However, to our knowledge, the currentported. The human homolog of Galgt2 is thought to
determine the Sda blood group antigen (Smith and Lowe, report is the first example of a naturally occurring pheno-
type resulting from ectopic expression of a component1994). Though there is currently no evidence for a human
Galgt2 mutation similar to Mvwf, our results demonstrate of the posttranslational processing machinery.
The altered tissue-specific pattern of glycosylationthat genetically determined alterations in glycosylation,
and potentially defects at other steps in posttransla- described here might be expected to perturb function
for a broad class of endothelial cell proteins. It is thustional processing, can result in profound reductions in
plasma VWF leading to a significant bleeding pheno- remarkable that the phenotype observed in the RIIIS/J
mouse is primarily restricted to a mild bleeding abnor-type. In addition, our findings further illustrate the utility
of the mouse as a model system for identifying modifier mality (Sweeney et al., 1990). This unexpected impact
on a specific protein product by a generalized alterationloci for complex mammalian phenotypes. Genetic mod-
ifiers identified in this way may also prove to be directly in posttranslational processing would have made it diffi-
cult to predict the molecular basis for Mvwf without therelevant to humans, as recently demonstrated for the
NRAMP1 gene and susceptibility to tuberculosis (Bel- aid of positional cloning methodologies. Of note, the
RIII pattern of staining was also observed in severallamy et al., 1998).
Prior studies suggest that approximately 60% of the other mouse strains not known to be related to RIII
(Ponder et al., 1985a). This latter observation, taken to-total variance in human plasma VWF level is determined
by genetic factors. The most significant of these factors gether with the novel molecular mechanism we have
defined, suggests that Mvwf may represent an ancientis the effect determined by the ABO blood type (Gill et
al., 1987), the latter accounting for 30% of this genetic founder allele among laboratory mice and a potential
site of variation among wild mouse populations.variation (Orstavik et al., 1985). ABO blood group is de-
termined by polymorphism in the glycosyltransferases The unusual observation of nearly identical pheno-
types in homozygotes and heterozygotes for the RIIIS/Jencoded by the ABO locus, and the resulting structures
are known to be present on N-linked sugar chains of allele of Mvwf (the presence of one or two gene copies
producing a similar effect), originally suggested that theplasma VWF (Sodetz et al., 1979). Though proposed to
alter plasma VWF processing, secretion, or stability (Gill mutant allele results from a gain-of-function mutation.
Pure dominant inheritance of this type is unusual amonget al., 1987), the precise mechanism for the effect of
the ABO locus on VWF level is unknown. A clearance human genetic disorders. In the few clear examples,
such as Huntington's disease (Huntington's Diseasemechanism similar to but more subtle than that we have
demonstrated for Mvwf may also explain the effect of Collaborative Research Group, 1993), the disease-caus-
ing mutation generally results in a coding sequenceABO in humans, as well as the known minor effects of
other blood group antigens (Orstavik et al., 1989). Our change leading to a new or altered protein function. In
contrast, the Mvwf gain-of-function is a switch in theresults also suggest that polymorphic variation in glyco-
syltransferase function or other steps in posttransla- tissue-specific pattern of expression, rather than an al-
teration in the protein product itself.tional processing may account for the large component
of genetic variation in VWF level that remains to be There are several well-described examples of inher-
ited human diseases associated with alterations in tem-identified. These potential modifier loci could be signifi-
cant determinants of genetic predisposition to thrombo- poral or developmental gene expression, such as hered-
itary persistence of fetal hemoglobin (Cunningham andsis and atherosclerosis through their effects on plasma
VWF levels (Lip and Blann, 1997). Jane, 1996) and factor IX Leiden (Crossley et al., 1992).
However, there are few precedents for a natural muta-Alterations in posttranslational processing, includ-
ing glycosylation, may represent an important general tion producing an altered tissue-specific pattern. De-
creased expression in normal tissue, concurrent withmechanism for genetic modifiers of human disease. Ge-
netically determined variation in glycosylation may be aberrant ectopic expression, has been observed in sev-
eral mouse mutations including the W-sash allele of theparticularly relevant for regulating the steady-state level
of plasma proteins such as VWF, as even small changes c-Kit receptor gene (Duttlinger et al., 1993), the Steel-
contrasted allele of the melanocyte growth factor genein carbohydrate structure could have profound effects
(Bedell et al., 1995), and a number of mutant alleles foron either processing through the secretory pathway or
the agouti coat color gene (Duhl et al., 1994). However,clearance mechanisms. In addition, given the large num-
in all of these examples, gene expression is altered fromber of genes participating in the assembly of N- and
a tissue-specific to a more general pattern. The uniqueO-linked glycoprotein structures (Varki, 1993), the op-
switch from one cell-specific pattern to another, as ob-portunity exists for considerable genetic diversity.
served for the Mvwf mutation, suggests a novel molecu-
lar mechanism. No obvious regulatory mutation has yet
Regulatory Changes in Gene Expression been detected by routine Southern blot analysis of
as Disease-Causing Mutations Galgt2 genomic structure or direct sequence analysis
Disease-causing mutations have been previously re- through the first 1.5 kb of the upstream promoter. How-
ported due to alteration at glycosylation sites within a ever, several of the transcriptional mutants described
target protein or loss-of-function for specific enzymes above act at a great distance, with responsible muta-
within the glycosylation pathway (Varki, 1993; Kornfeld, tions located as far as 400 kb from the relevant promot-
1998). In addition, transgenic misdirection of an N-ace- ers (Bedell et al., 1996). Though the Mvwf mutation may
similarly lie at a great distance from the Galgt2 gene, atylglucoaminyltrasferase to the liver was recently shown
A Modifier Gene for Plasma von Willebrand Factor
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more proximal location adjacent to the promoter or (Verma and Somia, 1997). However, our results suggest
that production of a recombinant plasma protein at alter-within an intron of the Galgt2 gene cannot be excluded.
Based on current genetic data (Mohlke et al., 1998), the native tissue sites, or in cells with a glycosylation pro-
gram distinct from wild-type, could have unexpectedMvwf mutation must lie somewhere within the 300 kb
interval surrounding Galgt2. consequences.
Experimental Procedures
Heterogeneity among Endothelial Cell
Gene Expression Programs RNA PCR and Sequencing
Small intestine and liver RNA from adult RIIIS/J, CASA/Rk, andThe absence of detectable GALGT2-modified VWF in
(RIIIS/J 3 CASA/Rk)F1 mice were isolated using TRIzol reagentthe plasma of RIIIS/J mice suggests that this large pool
(GIBCO-BRL, Gaithersburg, MD). RNA PCR was performed as de-of VWF is rapidly cleared. The source of the remaining
scribed (Nichols et al., 1998). To amplify the 59 portion of the Galgt2unmodified VWF in plasma is unclear. The RIIIS/J Galgt2
cDNA, corresponding to nucleotides 6±1031 of the published se-
allele may direct expression to a subset of endothelial quence (Smith and Lowe, 1994), small intestine RNA reverse-tran-
cells only partially overlapping the distribution of cells scribed with primer 1 (59-AGTAGTCACCTGTG-39) was amplified with
primers 2 (59-GTAGGCAGTCTGCAGAAGTGGCT-39) and 3 (59-CAGGexpressing the Vwf gene. The subset of unmodified VWF
TTCCTCCCAGCAAACCAG-39). Similarly, the 39 portion of Galgt2,molecules persisting in RIIIS/J plasma would thus repre-
nucleotides 973±1600, was reverse-transcribed with primer 4 (59-sent the product of a Vwf-positive/Galgt2-negative en-
GCCGCTAATCTGTT-39) and amplified with primers 5 (59-ACTACGTdothelial cell subpopulation. Alternatively, the unmodi-
GGAGTACTACACCATG-39) and 6 (59-ATTGCGATTCCTGGTCTTG
fied plasma VWF pool could represent a subset of VWF GTACT-39). For a control in the comparative expression study, equal
molecules that have escaped complete modification in quantities of Galgt2 39 RNA PCR products amplified from RIIIS/J
and CASA/Rk were combined prior to sequencing with primer 7 (59-Galgt2-expressing cells.
CTGGAGAAAACCGAACTGGATGTG-39). All comparative expres-It is becoming increasingly clear that the gene expres-
sion analyses were performed on independent samples from twosion program is highly variable among endothelial cells
different (RIIIS/J 3 CASA/Rk)F1 mice.of different vascular beds. Though frequently used as a
Primers used to sequence and test the relative allele expression
general marker for endothelial cells, VWF is known to of Atp6n1 were designed from mouse and rat cDNA sequences
be expressed at high levels in capillaries, veins, and (GenBank accession numbers L19737 and D13123). The Atp6n1
cDNA was reverse-transcribed from liver RNA samples using primervenules, with lower expression in most large arterial
8 (59-TAATGGTAAAGCTCA-39), amplified with primers 9 (59-GGGAGvessels (Rand et al., 1987). A portion of the human VWF
TGGGAGTGCAGATTGAA-39) and 10 (59-AGCAGGGACGGCTGGGTpromoter (2487 to 1246) has been shown to target
GAC-39), and sequenced with primer 10. Similarly, primers used toexpression to the yolk sac vasculature and to only a
analyze Gip were designed from mouse, rat, and human sequences
subset of endothelial cells in the adult brain (Aird et al., (GenBank accession numbers U34295, X66724, and M18185). The
1995). Similar age-restricted results were obtained in Gip cDNA was reverse-transcribed from small intestine RNA sam-
ples using primer 11 (59-GTTTGGTTCTCTCAGA-39), amplified withTie2-LacZ transgenic mice when only the promoter ele-
primers 12 (59-CTGTTTGGAGCAAGATCCTGAGAAC-39) and 13 (59-ment was included (Schlaeger et al., 1995). However
AAGCAGGAGCCAAGCAAGCTAAG-39), and sequenced with primerthe addition of a 10-kb intron 1 Tie2 enhancer element
14 (59-AGGAAGATGGTGGCTTTGAAGACCT-39).expanded expression specifically and uniformly through-
out the vasculature of both embryonic and adult mice
RNase Protection(Schlaeger et al., 1997). The observation that GALGT2
Ribonuclease protection assays were performed using the RPA II
may modify up to 95% of the total VWF plasma pool kit (Ambion Inc., Austin, TX). A Galgt2 DNA template containing a
suggests that the endothelial cell pattern conferred on T7 RNA polymerase recognition site was generated by PCR using
Galgt2 by the Mvwf mutation closely matches that of primers 59-GGCTCTTCCCCAAAAATCAGTGTG-39 and 59-GGATCCT
AATACGACTCACTATAGGGAGGGCTCTTCACTCTCTCAAG-39. Thethe Vwf gene. The transgenic expression of Galgt2 under
protected fragment corresponds to nucleotides 269±406 of thecontrol of the Tie2 promoter/enhancer would also ap-
Galgt2 cDNA (Smith and Lowe, 1994). A pTRI-b-actin-mouse plas-pear to have a very similar endothelial cell pattern. These
mid (Ambion, Inc.) was used as the template for the control actin
observations suggest that the Mvwf and Tie2 transcrip- probe. Riboprobes were labeled with [a-32P]UTP and transcribed
tion programs are both very broad, encompassing with T7 RNA polymerase using 100 ng of Galgt2 template and 500
nearly the full subset of endothelial cells expressing ng of actin template. To remove the DNA templates, riboprobes were
treated with 20 units of RNase-free DNase (Boehringer Mannheim,VWF. The future definition of the complex transcriptional
Indianapolis, IN) and were extracted using TRIzol Reagent. A totalelements within the RIIIS/J Mvwf allele may provide im-
of 105 cpm of riboprobe was added to 10 mg of sample RNA.portant insights into the regulation of endothelial cell±
specific gene expression. In addition, the shutoff of
ImmunofluorescenceGalgt2 expression in the gastrointestinal tract coinci-
Small intestine, spleen, and kidney blocks from RIIIS/J, CASA/Rk,dent with the endothelial cell±specific induction may
(RIIIS/J 3 CASA/Rk)F1, C57BL/6J, and Galgt2-deficient mice wereshed light on more general processes of tissue-specific prepared in O. C. T. compound (Tissue-Tek). Twelve-micrometer
gene regulation. sections were cut using a cryostat and air-dried at room temperature
for 30 min. Immunofluorescence was performed essentially as de-Taken together, our observations illustrate the poten-
scribed (Nichols et al., 1998). Tissue sections were blocked in 6%tial importance of tissue-specific differences in post-
goat serum, 0.05% Triton X-100, 0.05% Tween 20 in PBS. Sectionstranslational processing. Though variation in glycosyla-
were incubated with 5 mg/ml DBA-biotin (EY Laboratories, San Ma-tion across species and different cell types has been
teo, CA) and 28.5 mg/ml rabbit anti-human VWF (Dako, Carpinteria,
well described (Varki, 1993), this variability has generally CA) overnight at 48C, followed by incubation with 7.5 mg/ml FITC-
not presented a problem for the ectopic expression of avidin (EY Laboratories) and 1.2 mg/ml Texas red goat anti-rabbit
IgG (ICN Pharmaceuticals, Aurora, OH) for 1 hr at room temperature.proteins for therapeutic purposes, such as gene therapy
Cell
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Slides were mounted with Immuno Fluore Mounting Medium (ICN) Transgenic Mice
To express Galgt2 in endothelial cells, Galgt2 was placed under theand visualized at 100-fold magnification.
control of the previously described murine receptor tyrosine kinase
Tie2 promoter and enhancer (Schlaeger et al., 1997). The partial
RNA In Situ Hybridization Galgt2 cDNA used encompasses the entire coding region of the
RNA in situ hybridization was performed as described (Smith et al., gene (Smith and Lowe, 1994) but lacks most untranslated sequence.
1996) using frozen sections of small intestine, kidney, spleen, and To facilitate detection of the transgene on an endogenous back-
colon from 12-week-old RIIIS/J and C57BL/6J mice. The Galgt2 ground, 23 nucleotides of the 39 untranslated region were removed
probe consists of nucleotides 45±361 of the Galgt2 sequence (Smith by a PCR technique using the primer 59-GCTCTAGATGTTGCCCGC
and Lowe, 1994). Slides were exposed to emulsion for ten days to CGCTAATCTGTTCTTTTTAAGTGGAGCAGTAGAG-39 (an underline
four weeks. indicates the nucleotides flanking the deletion). The construct (Fig-
ure 6A) consisted of a 2.1 kb HindIII Tie2 promoter fragment followed
by a 1.6 kb XhoI Galgt2 cDNA fragment followed by an SV40 intronSynthesis of VWF Modified by GALGT2
and poly A signal derived from the pcDNA1/Amp vector (Invitrogen).Generation and maintenance of control CHO-Tag cells and Sda-
In addition the full 10 kb Tie2 enhancer, an NgoAIV/NotI fragmentCHO-Tag cells, engineered as a stable line expressing Galgt2, have
transferred through pBluescript II SK1 to generate a BssHII frag-been described previously (Smith and Lowe, 1994). The full-length
ment, is located after the poly A signal. Plasmids containing thehuman VWF cDNA in pMT2 also has been described previously
Tie2 promoter and enhancer were kindly provided by T. Sato (Univer-(Bonthron et al., 1986). The VWF-myc plasmid contains the human
sity of Texas Southwestern Medical Center). A NotI digest releasedVWF cDNA through the penultimate codon of the coding sequence
the 15 kb transgene from the pGEM5z (Promega, Madison, WI)cloned into the XbaI-EcoRI fragment of pcDNA3.1(2)Myc-His A vec-
vector.tor (Invitrogen, Carlsbad, CA). The resulting c-myc-epitope-tagged
Transgenic mice were generated in the Transgenic Core facilityVWF protein contains the following amino acids at the carboxyl
at the University of Michigan. Transgene DNA was injected intoend, following the penultimate residue of native VWF (serine 2812):
fertilized eggs produced by (C57BL/6 3 SJL)F1 parents. Pups wereRIPPHWTSGSELGTKLGPEQKLISEEDLNSAVDHHHHHH. CHO-Tag
genotyped using primers that span an intron as well as the 23-and Sda-CHO-Tag cells in 100 mm dishes were transiently trans-
nucleotide cDNA deletion: 59-TCCCATCTTGCAACGAGTGGC-39fected with 5 mg plasmid using approximately 35 ml LipofectAMINE
and 59-TTGTTGCCCGCCGCTAATCTGTT-39. Selected founder ani-(GIBCO-BRL), and recombinant VWF was collected in OptiMEM I
mals were mated to CASA/Rk, a strain previously shown to haveReduced Serum Media (GIBCO-BRL) 48±72 hrs after transfection.
plasma VWF levels z20-fold higher than RIIIS/J (Mohlke et al., 1996).Media was collected into a cocktail of protease inhibitors (5 mg/ml
Blood samples were collected by retro-orbital plexus puncture andaprotinin, 100 mg/ml trypsin inhibitor, 1 mM PMSF, 2.5 mM EDTA,
plasma VWF level was determined as previously described (Mohlke1 mg/ml pepstatin), clarified by centrifugation at 2100 3 g for 10
et al., 1996). While the reported plasma VWF level for foundermin, and concentrated 30- to 40-fold using Centriplus concentrators,
transgenic mice is based on a single blood sample, levels among100 kDa MW cutoff (Amicon, Beverly, MA).
progeny are the average of three samples obtained between four
and eight weeks of age. Average plasma VWF levels of transgenic
Clearance Studies and nontransgenic progeny were compared by two-tailed Student's
Plasma clearance studies were performed in 9-week-old male t test.
C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) anesthe-
tized with an intraperitoneal injection of sodium pentobarbital (ap- Acknowledgments
proximately 1 mg/g body weight). Mice remained anesthetized for
the duration of the experiment. 1.5±2 mg of VWF in a total volume We thank T. Sato (University of Texas Southwestern Medical Center)
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